The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 22, 2014
Filed:
Apr. 13, 2010
Young Woo Park, Daejeon, KR;
Kiwon JO, Yongin-si, KR;
Donghee Lee, Suwon-si, KR;
Jung Yu, Daejeon, KR;
Ji Hyun Park, Yuseong-gu, KR;
Chan-woong Park, Bucheon-si, KR;
Eun Jin Kim, Daegu, KR;
Yun Jung Park, Gyeonggi-do, KR;
Young Woo Park, Daejeon, KR;
Kiwon Jo, Yongin-si, KR;
Donghee Lee, Suwon-si, KR;
Jung Yu, Daejeon, KR;
Ji Hyun Park, Yuseong-gu, KR;
Chan-Woong Park, Bucheon-si, KR;
Eun Jin Kim, Daegu, KR;
Yun Jung Park, Gyeonggi-do, KR;
Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;
Abstract
A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.